LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article ; Online: Risk of COVID-19 infection, hospitalization, and mortality in patients with psoriasis treated by interleukin-17 inhibitors.

    Kridin, Khalaf / Schonmann, Yochai / Solomon, Arie / Damiani, Giovanni / Tzur Bitan, Dana / Onn, Erez / Weinstein, Orly / Cohen, Arnon Dov

    The Journal of dermatological treatment

    2022  Volume 33, Issue 4, Page(s) 2014–2020

    Abstract: ... determined.: Objective: To evaluate the risk of COVID-19, COVID-19-associated hospitalization, and ... mortality among patients with psoriasis treated by IL-17I.: Methods: A population-based cohort study was ... treatments: 0.65 (95% CI, 0.09-4.59)] and COVID-19-associated mortality [adjusted HR for IL-17I vs ...

    Abstract Background: The risk of the infection and its complications under this drug class remains to be determined.
    Objective: To evaluate the risk of COVID-19, COVID-19-associated hospitalization, and mortality among patients with psoriasis treated by IL-17I.
    Methods: A population-based cohort study was performed to compare psoriasis patients treated by IL-17I (
    Results: The use of IL-17I was not associated with an increased risk of COVID-19 infection [adjusted HR for IL-17I vs. methotrexate: 0.91 (95% CI, 0.48-1.72); IL-17I vs. non-systemic/non-immunomodulatory treatments: 0.92 (95% CI, 0.54-1.59)]. IL-17I was associated with comparable risk of COVID-19-associated hospitalization [adjusted HR for IL-17I vs. methotrexate: 0.42 (95% CI, 0.05-3.39); IL-17I vs. non-systemic/non-immunomodulatory treatments: 0.65 (95% CI, 0.09-4.59)] and COVID-19-associated mortality [adjusted HR for IL-17I vs. methotrexate: 7.57 (95% CI, 0.36-157.36); IL-17I vs. non-systemic/non-immunomodulatory treatments: 7.05 (95% CI, 0.96-51.98)]. In a sensitivity analysis, neither secukinumab nor ixekizumab imposed an elevated risk of any of the outcomes of interests.
    Conclusions: IL-17I treatment does not confer an increased risk of COVID-19 infection or its complications in patients with psoriasis. Our findings support the continuation of IL-17I treatment during the pandemic.
    MeSH term(s) Antibodies, Monoclonal/therapeutic use ; COVID-19 ; Cohort Studies ; Hospitalization ; Humans ; Interleukin Inhibitors ; Interleukin-17 ; Methotrexate/therapeutic use ; Psoriasis/chemically induced ; Psoriasis/drug therapy ; Severity of Illness Index
    Chemical Substances Antibodies, Monoclonal ; Interleukin Inhibitors ; Interleukin-17 ; Methotrexate (YL5FZ2Y5U1)
    Language English
    Publishing date 2022-03-21
    Publishing country England
    Document type Journal Article
    ZDB-ID 1036299-x
    ISSN 1471-1753 ; 0954-6634
    ISSN (online) 1471-1753
    ISSN 0954-6634
    DOI 10.1080/09546634.2021.1905766
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2627: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Risk of COVID-19 infection, hospitalization and mortality in psoriasis patients treated with interleukin-17 inhibitors: A systematic review and meta-analysis.

    Liu, Meitong / Wang, Huijuan / Liu, Lu / Cui, Saijin / Huo, Xiangran / Xiao, Zhuoyun / Zhao, Yaning / Wang, Bin / Zhang, Guoqiang / Wang, Na

    Frontiers in immunology

    2022  Volume 13, Page(s) 1046352

    Abstract: ... aimed to evaluate the effect of IL-17 inhibitors on the risk of COVID-19 infection, hospitalization, and ... differences in COVID-19 outcomes between psoriasis patients using IL-17 inhibitors and those using non ... safety and tolerability in the treatment of psoriasis. However, the use of IL-17 inhibitors in patients ...

    Abstract Background: Coronavirus disease 2019 (COVID-19) have brought great disaster to mankind, and there is currently no globally recognized specific drug or treatment. Severe COVID-19 may trigger a cytokine storm, manifested by increased levels of cytokines including interleukin-17 (IL-17), so a new strategy to treat COVID-19 may be to use existing IL-17 inhibitors, which have demonstrated efficacy, safety and tolerability in the treatment of psoriasis. However, the use of IL-17 inhibitors in patients with psoriasis during the COVID-19 pandemic remains controversial due to reports that IL-17 inhibitors may increase the risk of respiratory tract infections.
    Objectives: The systematic review and meta-analysis aimed to evaluate the effect of IL-17 inhibitors on the risk of COVID-19 infection, hospitalization, and mortality in patients with psoriasis.
    Methods: Databases (including Embase, PubMed, SCI-Web of Science, Scopus, CNKI, and the Cochrane Library) were searched up to August 23, 2022, for studies exploring differences in COVID-19 outcomes between psoriasis patients using IL-17 inhibitors and those using non-biologics. Two authors independently extracted data and assessed the risk of bias in a double-blind manner. The risk ratios (RRs) and 95% confidence intervals (CIs) were calculated and heterogeneities were determined by the
    Results: Nine observational studies involving 7,106 participants were included. The pooled effect showed no significant differences in the rates of SARS-CoV-2 infection (
    Conclusion: The use of IL-17 inhibitors in patients with psoriasis does not increase the risk of SARS-CoV-2 infection or worsen the course of COVID-19.
    Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42022335195.
    MeSH term(s) Humans ; COVID-19/drug therapy ; Interleukin-17 ; Interleukin Inhibitors ; Pandemics ; Antibodies, Monoclonal/therapeutic use ; SARS-CoV-2 ; Psoriasis/drug therapy ; Hospitalization ; Randomized Controlled Trials as Topic
    Chemical Substances Interleukin-17 ; Interleukin Inhibitors ; Antibodies, Monoclonal
    Language English
    Publishing date 2022-10-21
    Publishing country Switzerland
    Document type Meta-Analysis ; Systematic Review
    ZDB-ID 2606827-8
    ISSN 1664-3224 ; 1664-3224
    ISSN (online) 1664-3224
    ISSN 1664-3224
    DOI 10.3389/fimmu.2022.1046352
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top